Immunotherapy for metastatic non–small cell lung cancer: Is it really a no‐brainer?
There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non–small cell lung cancer (NSCLC); it is very important to expand research in this area because brain metastasis strongly affects patients' quality of l...
Gespeichert in:
| Veröffentlicht in: | Cancer Jg. 130; H. 15; S. 2577 - 2581 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Wiley Subscription Services, Inc
01.08.2024
|
| Schlagworte: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non–small cell lung cancer (NSCLC); it is very important to expand research in this area because brain metastasis strongly affects patients' quality of life and overall survival. This editorial reviews the available data in the context of a recent meta‐analysis of the pivotal IMpower130, IMpower131, and IMpower150 studies, which explores metastatic epidermal growth factor receptor and anaplastic lymphoma kinase wild‐type NSCLC to determine potential preventative factors and risk factors for the development of brain metastasis, specifically the question of whether immunotherapy (the anti–programmed death ligand 1 antibody, atezolizumab in particular) plays a role in preventing brain metastasis. |
|---|---|
| AbstractList | There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non–small cell lung cancer (NSCLC); it is very important to expand research in this area because brain metastasis strongly affects patients' quality of life and overall survival. This editorial reviews the available data in the context of a recent meta‐analysis of the pivotal IMpower130, IMpower131, and IMpower150 studies, which explores metastatic epidermal growth factor receptor and anaplastic lymphoma kinase wild‐type NSCLC to determine potential preventative factors and risk factors for the development of brain metastasis, specifically the question of whether immunotherapy (the anti–programmed death ligand 1 antibody, atezolizumab in particular) plays a role in preventing brain metastasis. |
| Author | Halmos, Balazs Young, Lauren K. |
| Author_xml | – sequence: 1 givenname: Lauren K. orcidid: 0000-0003-1460-5257 surname: Young fullname: Young, Lauren K. organization: Albert Einstein College of Medicine – sequence: 2 givenname: Balazs orcidid: 0000-0001-7548-8360 surname: Halmos fullname: Halmos, Balazs email: bahalmos@montefiore.org organization: Albert Einstein College of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38709894$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90c9KwzAcB_AgitvUiw8gAS8iVH9Jmib1IjL8MxAFUfRW0izVSpvOpEV22yMIvuGexMxNDx68JIR8knzJd4DWbWMNQrsEjggAPdZWuyPGGYc11CeQighITNdRHwBkxGP21EMD71_DUlDONlGPSQGpTOM-ehzVdWeb9sU4NZnionG4Nq3yrWpLjcND89mnr1VVYW3CUHX2GWtltXEneORx2WJnwu4Uq4Dns4_cqdIad7qNNgpVebOzmrfQw8X5_fAqur69HA3PriNN4wQioY2kUIS8Wo6LxFAuQeUJpSYWpFBEcgI6F2PNc60hlqJIuRAsF5BollPNttDB8t6Ja94649usLv0iqrKm6XzGgJOUpYkkge7_oa9N52xIF5SkktE4ZUHtrVSX12acTVxZKzfNfr4sgMMl0K7x3pnilxDIFn1kiz6y7z4CJkv8XlZm-o_MhjfDu-WZL8AxjQA |
| Cites_doi | 10.1200/JCO.2004.12.149 10.1016/s1470‐2045(19)30167‐6 10.1016/S0140-6736(16)32517-X 10.1177/1758835918769391 10.1056/NEJMoa2306434 10.1016/j.lungcan.2018.12.017 10.1002/cncr.35242 10.1016/j.jtocrr.2021.100205 10.1515/med-2020-0192 10.1016/j.jtho.2022.10.014 10.1080/2162402X.2022.2059874 10.1016/S1470‐2045(20)30111‐X 10.21037/tlcr‐23‐245 10.1056/NEJMoa1501824 10.1016/j.jtho.2020.03.028 10.1200/JCO.21.01308 10.1016/j.jtho.2023.06.017 10.1200/JCO.22.02561 10.1056/NEJMoa1716948 10.1038/s41598‐019‐54513‐3 10.1016/S0140‐6736(15)01281‐7 10.1186/s12943-023-01818-7 10.3390/cancers15030844 10.1016/j.lungcan.2023.107322 |
| ContentType | Journal Article |
| Copyright | 2024 American Cancer Society. |
| Copyright_xml | – notice: 2024 American Cancer Society. |
| DBID | AAYXX CITATION NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| DOI | 10.1002/cncr.35350 |
| DatabaseName | CrossRef PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0142 |
| EndPage | 2581 |
| ExternalDocumentID | 38709894 10_1002_cncr_35350 CNCR35350 |
| Genre | editorial Editorial Commentary |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- AAMMB AAQOH AAYXX AEFGJ AEYWJ AFFNX AGHNM AGNAY AGXDD AGYGG AI. AIDQK AIDYY C1A CITATION EJD EMOBN HF~ H~9 J5H LW6 N4W NEJ O8X OHT RSU VH1 WHG Y6R YQJ ZXP NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c2460-7ce820f014c8df6e2580ab622e471fa18510cb7dc5bcc0487f95773b706c3b2c3 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001214390100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Mon Sep 29 05:36:47 EDT 2025 Tue Oct 07 07:17:45 EDT 2025 Thu Apr 03 06:59:32 EDT 2025 Sat Nov 29 07:09:03 EST 2025 Wed Jan 22 17:17:39 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 15 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2460-7ce820f014c8df6e2580ab622e471fa18510cb7dc5bcc0487f95773b706c3b2c3 |
| Notes | SourceType-Scholarly Journals-1 content type line 14 ObjectType-Editorial-2 ObjectType-Commentary-1 content type line 23 |
| ORCID | 0000-0001-7548-8360 0000-0003-1460-5257 |
| PMID | 38709894 |
| PQID | 3082832493 |
| PQPubID | 2045183 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_3051939681 proquest_journals_3082832493 pubmed_primary_38709894 crossref_primary_10_1002_cncr_35350 wiley_primary_10_1002_cncr_35350_CNCR35350 |
| PublicationCentury | 2000 |
| PublicationDate | 1 August 2024 |
| PublicationDateYYYYMMDD | 2024-08-01 |
| PublicationDate_xml | – month: 08 year: 2024 text: 1 August 2024 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2024 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 372 2004; 22 2023; 41 2019; 9 2023; 22 2023; 12 2021; 2 2019; 20 2023; 18 2023; 15 2023; 184 2022; 40 2018; 378 2016; 387 2020; 15 2023; 389 2019; 128 2024 2020; 21 2022; 11 2016; 389 e_1_2_3_2_1 e_1_2_3_6_1 e_1_2_3_16_1 e_1_2_3_5_1 e_1_2_3_17_1 e_1_2_3_4_1 e_1_2_3_18_1 e_1_2_3_3_1 e_1_2_3_19_1 e_1_2_3_12_1 e_1_2_3_9_1 e_1_2_3_13_1 e_1_2_3_8_1 e_1_2_3_14_1 e_1_2_3_7_1 e_1_2_3_15_1 e_1_2_3_30_1 e_1_2_3_31_1 e_1_2_3_10_1 e_1_2_3_11_1 e_1_2_3_27_1 e_1_2_3_28_1 e_1_2_3_29_1 e_1_2_3_23_1 e_1_2_3_24_1 e_1_2_3_25_1 e_1_2_3_26_1 e_1_2_3_20_1 e_1_2_3_21_1 e_1_2_3_22_1 |
| References_xml | – volume: 15 issue: 3 year: 2023 article-title: Advances in the management of central nervous system metastases in non‐small cell lung cancer publication-title: Cancers – volume: 18 start-page: 1703 issue: 12 year: 2023 end-page: 1713 article-title: Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta‐analysis publication-title: J Thorac Oncol – volume: 20 start-page: 924 issue: 7 year: 2019 end-page: 937 article-title: Atezolizumab in combination with carboplatin plus nab‐paclitaxel chemotherapy compared with chemotherapy alone as first‐line treatment for metastatic non‐squamous non‐small‐cell lung cancer (IMpower130): a multicentre, randomised, open‐label, phase 3 trial publication-title: Lancet Oncol – volume: 11 issue: 1 year: 2022 article-title: Immune suppressive microenvironment in brain metastatic non‐small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060) publication-title: Oncoimmunology – volume: 378 start-page: 2288 issue: 24 year: 2018 end-page: 2301 article-title: Atezolizumab for first‐line treatment of metastatic nonsquamous NSCLC publication-title: N Engl J Med – volume: 389 start-page: 1935 issue: 21 year: 2023 end-page: 1948 article-title: Osimertinib with or without chemotherapy in EGFR‐mutated advanced non‐small cell lung cancer publication-title: N Engl J Med – volume: 389 start-page: 255 issue: 10066 year: 2016 end-page: 265 article-title: Atezolizumab versus docetaxel in patients with previously treated non‐small‐cell lung cancer (OAK): a phase 3, open‐label, multicentre randomised controlled trial publication-title: Lancet – volume: 2 issue: 8 year: 2021 article-title: Outcomes with pembrolizumab monotherapy in patients with programmed death‐ligand 1‐positive NSCLC with brain metastases: pooled analysis of KEYNOTE‐001, 010, 024, and 042 publication-title: JTO Clin Res Rep – volume: 22 year: 2023 article-title: Immunotherapy: an emerging modality to checkmate brain metastasis publication-title: Mol Cancer – volume: 128 start-page: 105 year: 2019 end-page: 112 article-title: Atezolizumab in patients with advanced non‐small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study publication-title: Lung Cancer – volume: 41 start-page: 4478 issue: 28 year: 2023 end-page: 4485 article-title: Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non‐small‐cell lung cancer with untreated brain metastases (Atezo‐Brain, GECP17/05) publication-title: J Clin Oncol – volume: 40 start-page: 1301 issue: 12 year: 2022 end-page: 1311 article-title: Five‐year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non‐small‐cell lung cancer publication-title: J Clin Oncol – year: 2024 article-title: Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150 publication-title: Cancer – volume: 21 start-page: 655 issue: 5 year: 2020 end-page: 663 article-title: Pembrolizumab for management of patients with NSCLC and brain metastases: long‐term results and biomarker analysis from a non‐randomised, open‐label, phase 2 trial publication-title: Lancet Oncol – volume: 387 start-page: 1540 issue: 10027 year: 2016 end-page: 1550 article-title: Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell lung cancer (KEYNOTE‐010): a randomised controlled trial publication-title: Lancet – volume: 22 start-page: 2865 issue: 14 year: 2004 end-page: 2872 article-title: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System publication-title: J Clin Oncol – volume: 9 issue: 1 year: 2019 article-title: Bevacizumab for the treatment of non‐small cell lung cancer patients with synchronous brain metastases publication-title: Nature – volume: 15 start-page: 1351 issue: 8 year: 2020 end-page: 1360 article-title: Atezolizumab in combination with carboplatin and nab‐paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial publication-title: J Thorac Oncol – volume: 18 start-page: 204 issue: 2 year: 2023 end-page: 222 article-title: First‐line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3‐year clinical update and outcomes in patients with brain metastases or select somatic mutations publication-title: J Thorac Oncol – volume: 12 start-page: 1636 issue: 7 year: 2023 end-page: 1642 article-title: Long‐term benefit of immunotherapy in metastatic non‐small cell lung cancer: the tale of the tail publication-title: Transl Lung Cancer Res – volume: 15 start-page: 589 issue: 1 year: 2020 end-page: 597 article-title: Bevacizumab for non‐small cell lung cancer patients with brain metastasis: a meta‐analysis publication-title: Open Med – volume: 184 year: 2023 article-title: Progress of immune checkpoint inhibitors therapy for non‐small cell lung cancer with brain metastases publication-title: Lung Cancer – volume: 372 start-page: 2018 issue: 21 year: 2015 end-page: 2028 article-title: Pembrolizumab for the treatment of non‐small‐cell lung cancer publication-title: N Engl J Med – volume: 15 year: 2023 article-title: Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? publication-title: Ther Adv Med Oncol – ident: e_1_2_3_4_1 doi: 10.1200/JCO.2004.12.149 – ident: e_1_2_3_17_1 doi: 10.1016/s1470‐2045(19)30167‐6 – volume-title: Pembrolizumab and Bevacizumab in Treating Patients With Metastatic Melanoma or Non‐Small Cell Lung Cancer With Untreated Brain Metastases ident: e_1_2_3_29_1 – ident: e_1_2_3_23_1 doi: 10.1016/S0140-6736(16)32517-X – ident: e_1_2_3_12_1 doi: 10.1177/1758835918769391 – volume-title: Blood‐Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets ident: e_1_2_3_30_1 – ident: e_1_2_3_31_1 – ident: e_1_2_3_5_1 doi: 10.1056/NEJMoa2306434 – volume-title: Pembrolizumab and Lenvatinib for the Treatment of Triple‐Negative Breast Cancer, Non‐Small Cell Lung Cancer, and Other Tumors With Brain Metastases ident: e_1_2_3_27_1 – ident: e_1_2_3_24_1 doi: 10.1016/j.lungcan.2018.12.017 – ident: e_1_2_3_6_1 doi: 10.1002/cncr.35242 – ident: e_1_2_3_10_1 doi: 10.1016/j.jtocrr.2021.100205 – ident: e_1_2_3_16_1 doi: 10.1515/med-2020-0192 – ident: e_1_2_3_11_1 doi: 10.1016/j.jtho.2022.10.014 – ident: e_1_2_3_22_1 doi: 10.1080/2162402X.2022.2059874 – ident: e_1_2_3_13_1 doi: 10.1016/S1470‐2045(20)30111‐X – volume-title: Cemiplimab for the Treatment of Untreated Brain Metastases from PD‐L1 >= 50% Non‐Small Cell Lung Cancer ident: e_1_2_3_26_1 – ident: e_1_2_3_7_1 doi: 10.21037/tlcr‐23‐245 – ident: e_1_2_3_8_1 doi: 10.1056/NEJMoa1501824 – volume-title: Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab for the Treatment of Non‐Squamous Non‐Small Cell Lung Cancer and Untreated Brain Metastases ident: e_1_2_3_28_1 – ident: e_1_2_3_18_1 doi: 10.1016/j.jtho.2020.03.028 – ident: e_1_2_3_25_1 doi: 10.1200/JCO.21.01308 – ident: e_1_2_3_2_1 doi: 10.1016/j.jtho.2023.06.017 – ident: e_1_2_3_14_1 doi: 10.1200/JCO.22.02561 – ident: e_1_2_3_19_1 doi: 10.1056/NEJMoa1716948 – ident: e_1_2_3_15_1 doi: 10.1038/s41598‐019‐54513‐3 – ident: e_1_2_3_9_1 doi: 10.1016/S0140‐6736(15)01281‐7 – ident: e_1_2_3_20_1 doi: 10.1186/s12943-023-01818-7 – ident: e_1_2_3_3_1 doi: 10.3390/cancers15030844 – ident: e_1_2_3_21_1 doi: 10.1016/j.lungcan.2023.107322 |
| SSID | ssj0007253 |
| Score | 2.457391 |
| Snippet | There is still much progress to be made in understanding the underlying mechanisms of brain metastasis development and its optimal therapy in non–small cell... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 2577 |
| SubjectTerms | Apoptosis Brain Brain cancer Growth factors Immunotherapy Kinases Lung cancer Lymphoma Metastases Monoclonal antibodies Non-small cell lung carcinoma Protein-tyrosine kinase Quality of life Risk factors Small cell lung carcinoma Targeted cancer therapy |
| Title | Immunotherapy for metastatic non–small cell lung cancer: Is it really a no‐brainer? |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.35350 https://www.ncbi.nlm.nih.gov/pubmed/38709894 https://www.proquest.com/docview/3082832493 https://www.proquest.com/docview/3051939681 |
| Volume | 130 |
| WOSCitedRecordID | wos001214390100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1097-0142 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bSsQwEB28Ib54v9TLEtEnodpN2qYVQWR1cUEXEcV9K0mahYVapV0F3_wEwT_0S5y03YoIgvhWaELCZC5n0s4ZgN1Ae1zGLmYnXAjbpTq0pe9L28fgEBp6Fc3iotkE73aDXi-8GoOjUS1MyQ9RX7gZyyj8tTFwIfODL9JQlapsn3msSNibbtO0L7jrdGs3zGlFQekEtueyXs1NSg--pn6PRj8g5nfEWoSc9tz_NjsPsxXUJCelbizAmE4XYfqy-pi-BHcdUxtSVWC9EESv5F4PhSkxGiiSPqQfr-_5vUgSYm73SYJugSijJNkh6eRkMCQIOJPkhQgc_PH6Jk23CZ0dL8Nt--ymdW5XfRZsRV3fsbnSiAP6mCypIO77mnqBI6RPqcbI1RcY0ZuOkjxWnlQKLZ73Q49zJrnjKyapYiswgZvSa0BiLrUrledLTNTCkEsqGc4Qwm3G3PEcC3ZG8o4eSzqNqCROppGRUVTIyILN0VFElUnlkeHVQffjhsyC7fo1GoORgUj1w5MZYwBpiIpmwWp5hPUyDD2TYZu3YK84qV_Wj1rd1nXxtP6XwRswQxHylL8HbsLEMHvSWzClnoeDPGvAOO8FDZg8vW7fXjQKXf0EqUzp_w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fa9swED9GN7q9rOv-1Wu2aXRPAzeOZFv2XsYIKw1tTCkdzZuRZBkCjjOctNC3fITBvmE-ye5sx6EMBmNvBkvInO7P72Td7wA-RjaQOvMxO5FKuT63savDULshBoeY6FWsyOpmEzJJoskkvmjv5lAtTMMP0R24kWXU_poMnA6k-1vWUFOa6lgEgjL2hz4iDerccD1KOkcseUtC6UVu4ItJx07K-9u59-PRHyDzPmatg87J3n9-7jN42qJN9rVRj314YMvnsDtu_6e_gOsRlYe0RVh3DAEsm9mloiqjqWHlvFyvfi1mqigYHfCzAj0DM6Qn1Wc2WrDpkiHmLIo7pnDwevVTU8MJW315Cd9Pvl0NT9221YJruB96rjQWoUCO-ZKJsjy0PIg8pUPOLQavXGFQH3hGy8wE2hg0epnHgZRCSy80QnMjXsEOfpQ9AJZJbX1tglBjrhbHUnMtcIZS_iCTXuA5cLQRePqjYdRIG-5knpKM0lpGDvQ2e5G2VrVIiVoHPZAfCwc-dK_RHkgGqrTzGxpDmDRGXXPgdbOH3TICnRMRzjvwqd6qv6yfDpPhZf305l8Gv4fHp1fj8_R8lJwdwhOOCKi5LdiDnWV1Y9_CI3O7nC6qd7Wq_gZsueuV |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fS9xAEB_kFOlLtWo1_qlb7JOQGneTbOKLyNnDQ3uIVLy3sLvZwEGMR-6u4JsfodBv6CdxJokREYTSt0B22WV2_vwm2fkNwLfIBlKnPmYnUinX5zZ2dRhqN8TgEBO9ihVp1WxCDgbRcBhfNndzqBam5odoP7iRZVT-mgzcjtPs4IU11BSm_C4CQRn7vE9dZDowf3rVu75oXbHkDQ2lF7mBL4YtPyk_eJn9OiK9gZmvUWsVdnpL_7nhZfjY4E12UivIJ5izxQos_mz-qK_CTZ8KRJoyrHuGEJbd2qmiOqORYcVd8fjwd3Kr8pzRJ36Wo29ghjSlPGL9CRtNGaLOPL9nCgc_PvzR1HLClsdrcN378at75jbNFlzD_dBzpbEIBjLMmEyUZqHlQeQpHXJuMXxlCsP6oWe0TE2gjUGzl1kcSCm09EIjNDfiM3RwU3YDWCq19bUJQo3ZWhxLzbXAGUr5h6n0As-BvWeBJ-OaUyOp2ZN5QjJKKhk5sP18FkljV5OEyHXQB_mxcOBr-xotgmSgCns3ozGESmPUNgfW6zNslxHonohy3oH96qjeWT_pDrpX1dPmvwzehcXL015y0R-cb8EHjhCovi64DZ1pObM7sGB-T0eT8kujq0_Xiew- |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunotherapy+for+metastatic+non%E2%80%93small+cell+lung+cancer%3A+Is+it+really+a+no%E2%80%90brainer%3F&rft.jtitle=Cancer&rft.au=Young%2C+Lauren+K&rft.au=Halmos%2C+Balazs&rft.date=2024-08-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=130&rft.issue=15&rft.spage=2577&rft.epage=2581&rft_id=info:doi/10.1002%2Fcncr.35350&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |